| Parkinson Disease
Ongentys vs Rytary
Side-by-side clinical, coverage, and cost comparison for parkinson disease.Deep comparison between: Ongentys vs Rytary with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRytary has a higher rate of injection site reactions vs Ongentys based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rytary but not Ongentys, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ongentys
Rytary
At A Glance
Oral
Daily
COMT inhibitor
Oral
Three to five times daily
Dopamine precursor/decarboxylase inhibitor combination
Indications
- Parkinson Disease
- Parkinson Disease
- Parkinson Disease, Postencephalitic
- Carbon monoxide-induced parkinsonism
- Manganese-induced parkinsonism
Dosing
Parkinson Disease 50 mg orally once daily at bedtime; avoid food 1 hour before and at least 1 hour after dose; reduce to 25 mg in moderate hepatic impairment (Child-Pugh B); avoid use in severe hepatic impairment (Child-Pugh C).
Parkinson Disease, Parkinson Disease Postencephalitic, Carbon monoxide-induced parkinsonism, Manganese-induced parkinsonism (levodopa-naive) Starting dose 23.75 mg/95 mg orally three times daily for 3 days; may increase to 36.25 mg/145 mg three times daily on day 4; titrate up to a maximum of 97.5 mg/390 mg three to five times daily; maximum daily dose 612.5 mg/2,450 mg.
Converting from immediate-release carbidopa-levodopa Calculate current total daily levodopa dose; initiate RYTARY at the recommended conversion dose (855 mg to 2,340 mg total daily levodopa depending on prior dose); administer in divided doses three to five times daily; maximum daily dose 612.5 mg/2,450 mg.
Contraindications
- Concomitant use of non-selective monoamine oxidase (MAO) inhibitors
- Pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms
- Concurrent use of nonselective MAO inhibitors (e.g., phenelzine, tranylcypromine) or use within the preceding 2 weeks
Adverse Reactions
Most common (>=4%) Dyskinesia, constipation, blood creatine kinase increased, hypotension/syncope, weight decreased
Serious Cardiovascular effects with COMT-metabolized drugs, falling asleep during activities of daily living, hypotension/syncope, dyskinesia, hallucinations and psychosis, impulse control/compulsive disorders, withdrawal-emergent hyperpyrexia and confusion
Postmarketing Fall
Most common (>=5%) Nausea, dizziness, headache, insomnia, abnormal dreams, dry mouth, dyskinesia, anxiety, constipation, vomiting, orthostatic hypotension
Serious Falling asleep during activities of daily living, somnolence, withdrawal-emergent hyperpyrexia and confusion, cardiovascular ischemic events, hallucinations/psychosis, impulse control/compulsive behaviors, dyskinesia, vitamin B6 deficiency and seizures, peptic ulcer disease, glaucoma
Postmarketing Suicide attempt, suicidal ideation
Pharmacology
Opicapone is a peripheral, selective and reversible inhibitor of catechol-O-methyltransferase (COMT) that reduces levodopa breakdown to 3-OMD, thereby increasing levodopa exposure in Parkinson's disease patients treated with levodopa/carbidopa.
Carbidopa inhibits peripheral decarboxylation of levodopa, increasing the amount available to cross the blood-brain barrier, where levodopa is converted to dopamine to relieve the symptoms of Parkinson's disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ongentys
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Rytary
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (5/12) · Qty limit (5/12)
UnitedHealthcare
Ongentys
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (2/8) · Qty limit (1/8)
Rytary
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (2/8) · Qty limit (0/8)
Humana
Ongentys
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Rytary
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Ongentys.
No savings programs available for Rytary.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OngentysView full Ongentys profile
RytaryView full Rytary profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.